Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/164735
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis

AuthorsVázquez-Bourgon, Javier; Pérez-Iglesias, Rocío; Ortiz-Garcia de la Foz, Victor; Suárez Pinilla, Paula; Díaz, Álvaro CSIC ORCID; Crespo-Facorro, Benedicto
KeywordsGlucose
Weight gain
Medication-naïve
Cholesterol
Triglycerides
Second-generation antipsychotic
Issue Date2018
PublisherSpringer Nature
CitationPsychopharmacology 235(1): 245-255 (2018)
Abstract[Introduction]: The use of second-generation antipsychotics (SGA) has been associated with metabolic changes. However, there are differences in the metabolic profile between SGAs. We have previously observed that ziprasidone had a more benign early metabolic profile compared to aripiprazole and quetiapine. However, a long-term follow-up is preferred to detect clinically relevant impairment in metabolic parameters. We aimed to compare the effect of aripiprazole, ziprasidone, and quetiapine on metabolic measures in first-episode non-affective psychosis patients after 1 year of treatment. [Material and methods]: One hundred and sixty-five drug-naïve patients, suffering from a first episode of non-affective psychosis, were randomly assigned to receive quetiapine, ziprasidone, or aripiprazole. Weight and glycemic/lipid parameters were recorded at baseline and after 1 year of treatment. [Results]: After 1 year of antipsychotic treatment, we found significant increments in weight, BMI, total cholesterol, LDL-cholesterol, triglycerides, and the triglyceride/HDL index in the sample as a whole. These changes produced a significant rise in the percentage of patients with obesity, hypercholesterolemia, and hypertriglyceridemia. However, when comparing the differential effect of each antipsychotic medication, we found no significant differences in any of the metabolic parameters between antipsychotics groups after 1 year of treatment. [Conclusion]: We concluded that the antipsychotics studied present similar metabolic profiles. However, the primary exposure to SGAs during the first year of psychosis was associated with significant increases in weight and metabolic parameters, leading to increments in obesity, hypertriglyceridemia, and hypercholesterolemia.
URIhttp://hdl.handle.net/10261/164735
DOI10.1007/s00213-017-4763-x
Identifiersdoi: 10.1007/s00213-017-4763-x
e-issn: 1432-2072
issn: 0033-3158
Appears in Collections:(IBBTEC) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

PubMed Central
Citations

7
checked on Nov 23, 2021

SCOPUSTM   
Citations

19
checked on Nov 30, 2021

WEB OF SCIENCETM
Citations

18
checked on Dec 1, 2021

Google ScholarTM

Check

Altmetric

Dimensions


Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.